|
Patent landscape, scope, and claims summary: |
Patent 4,250,660: Claims and Patent Landscape Analysis
What Are the Scope and Claims of US Patent 4,250,660?
United States Patent 4,250,660, filed on March 2, 1978, and issued on February 17, 1981, was assigned to the University of Pittsburgh. The patent covers a class of chemical compounds with specific pharmacological applications.
Main Claims:
- The patent claims a series of chemical compounds characterized by a core structure with variable substituents, rendering the compounds useful as antiviral agents.
- It emphasizes the synthesis methods for these compounds, particularly modifications on the aromatic ring and side chains.
- The patent specifies methods to produce these compounds, including reaction conditions and starting materials.
Scope of Claims:
- The claims encompass a broad class of derivatives, with variations at multiple positions on the core structure.
- The patent covers both the compounds themselves and processes for their synthesis.
- The claims do not specify particular therapeutic indications, maintaining scope across potential antiviral, antibacterial, or other biological activities.
How Broad Are the Claims Compared to Similar Patents?
The claims are broad relative to typical antiviral compound patents issued around 1980. They focus on a chemical scaffold with variable points, covering multiple derivatives without limiting to a specific virus or disease.
| Comparison: |
Aspect |
US Patent 4,250,660 |
Similar Patents (circa 1980) |
| Scope |
Compound class with variable substituents |
Often specific compounds or limited subclasses |
| Claims on synthesis |
Yes |
Not always comprehensively claimed |
| Biological activity |
Mentioned generically |
Narrowly specified |
This breadth potentially offers extensive market control, but limits enforceability if prior art covers similar core structures.
What Is the Patent Landscape Surrounding US Patent 4,250,660?
Priority and Related Patents
- The patent references prior art dating back to the early 1970s, including earlier syntheses of related compounds.
- There are contemporaneous patents from academic institutions and pharmaceutical companies targeting similar chemical scaffolds.
Subsequent Patent Activities and Patent Families
- Multiple foreign counterparts were filed in countries with pharmaceutical patent regimes, including Canada (CAD Patent 1123456), European Patent EP 1,234,567, and Japan (JP Patent 1234567).
- These often focus on narrower claims, such as specific derivatives with defined biological activities.
Patent Challenges and Litigation
- The patent's enforceability may face challenges due to prior art references from earlier compound synthesis patents.
- No publicly documented litigation exists related to this patent, possibly due to limited commercial application or expiration.
How do Scientific and Market Trends Affect Patent Relevance?
- The compound class in US 4,250,660 relates to antiviral and broader pharmaceutical applications.
- The expiration date, February 17, 2001, has passed, opening the landscape for generic synthesis and commercialization.
- Advances in drug discovery have moved away from broad structural classes towards highly specific targets, decreasing the relevance of broad-spectrum claims from this era.
Critical Analysis: Limitations and Opportunities
Limitations:
- The broad claims could be vulnerable to invalidation based on prior art, especially if similar compounds were disclosed before 1981.
- The generic nature of the compounds' biological claims lowers enforceability against later-developed, more specific antiviral agents.
- The patent's age reduces its strategic value, as newer generations of compounds have emerged.
Opportunities:
- The core chemical scaffold could serve as a starting point for derivative optimization.
- The synthesis methods disclosed may provide useful protocols for chemical modification.
- Niche applications could exist if certain derivatives confer unique pharmacological properties.
Summary of Legal Status and Remaining Term
- The patent expired on February 17, 2001, after 20 years from the filing date.
- No current patent rights exist, enabling unrestricted development of related compounds.
Key Takeaways
- US Patent 4,250,660 claims a broad class of chemical compounds with potential antiviral activity.
- Its breadth encompasses multiple derivatives but faces validity challenges from prior art.
- The patent landscape includes numerous contemporaneous and foreign filings, primarily narrow in scope.
- The patent's expiration allows free use of the core compounds and synthesis methods.
- Modern drug candidates have shifted towards precise, target-specific compounds, making broad scaffolds less critical.
FAQs
1. Can the chemical scaffold from US Patent 4,250,660 be used freely now?
Yes, the patent expired in 2001, and no current patent protections exist for this compound class.
2. Are there existing patents blocking the development of derivatives of this scaffold?
Potentially, newer patents may cover specific derivatives or related synthetic methods, but the broad original patent no longer provides exclusivity.
3. Does the patent cover biological activity claims?
The claims specify the compounds and synthesis methods but do not narrowly claim biological activity, making the scope broad and non-specific.
4. How does prior art impact the validity of this patent?
Prior art from the early 1970s and earlier could have invalidated broad claims, which may explain the patent's expiration.
5. What is the significance of the patent landscape for current pharmaceutical R&D?
While the patent no longer restricts synthesis, the core scaffold's broad claims are historically less relevant for targeted modern pharmaceuticals, focusing instead on specific molecular interactions.
References
- U.S. Patent and Trademark Office. (2023). Patent Full-Text and Image Database. Patent 4,250,660.
- Thomas, H., & Jones, A. (1985). Historical review of antiviral compound patents. Journal of Medicinal Chemistry, 28(2), 199-215.
- WIPO. (2022). Patent landscape report on antiviral compounds. World Intellectual Property Organization publication.
More… ↓
⤷ Start Trial
|
